labetalol has been researched along with enalapril in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Erley, CM; Harrer, U; Krämer, BK; Risler, T | 1 |
| Applegate, WB; Borhani, N; DeQuattro, V; Due, DL; Kaihlanen, PM; Oishi, S; Sirgo, MA | 1 |
| Edwards, LD; Guerrero-Sierra, J; Guiducci, U; Renaud, H; Rodriguez-Saavedra, M; Sack, DW; Zannad, FM | 1 |
| Gonzalez, DG; Ram, CV | 1 |
| Aydelotte, ME; White, WB | 1 |
| Elghozi, JL; Meyer, P; Saad, MA | 1 |
| Lowenthal, DT | 1 |
| Groshong, T | 1 |
| Weber, MA | 1 |
| Chams, N; Gjeka, R; Kumar, S; Peterson, D; Ross, I; Salman, A; Salman, J; Tegeltija, V | 1 |
2 review(s) available for labetalol and enalapril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Cardiovascular Diseases; Clinical Trials as Topic; Enalapril; Ethanolamines; Female; Heart Failure; Hemodynamics; Humans; Hypertension; Labetalol; Losartan; Male; Metoprolol; Middle Aged; Nebivolol; Nifedipine; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Sympathomimetics | 2005 |
3 trial(s) available for labetalol and enalapril
| Article | Year |
|---|---|
Renal hemodynamics and reduction of proteinuria by a vasodilating beta blocker versus an ACE inhibitor.
Topics: Adult; Blood Pressure; Double-Blind Method; Enalapril; Female; Glomerular Filtration Rate; Humans; Labetalol; Male; Proteinuria; Renal Circulation | 1992 |
Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Electrocardiography, Ambulatory; Enalapril; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle Aged | 1991 |
Comparison of dilevalol and enalapril administered once daily for mild hypertension.
Topics: Adult; Aged; Double-Blind Method; Enalapril; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle Aged; Multicenter Studies as Topic; Random Allocation; Supination | 1989 |
15 other study(ies) available for labetalol and enalapril
| Article | Year |
|---|---|
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
New approaches for the treatment of hypertensive urgencies and emergencies.
Topics: Antihypertensive Agents; Captopril; Emergencies; Enalapril; Humans; Hypertension; Labetalol; Nifedipine | 1988 |
Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Humans; Hypertension; Hypertension, Renovascular; Labetalol; Male; Middle Aged | 1988 |
Baroreflex sensitivity alteration following transient hemispheric ischaemia in rats: protective effect of alphamethyldopa and guanfacine.
Topics: Animals; Blood Pressure; Enalapril; Guanfacine; Guanidines; Heart Rate; Ischemic Attack, Transient; Labetalol; Male; Methyldopa; Nicardipine; Phenylacetates; Pressoreceptors; Rats; Rats, Inbred Strains; Reflex; Tachycardia | 1986 |
New drugs for hypertension.
Topics: Antihypertensive Agents; Bumetanide; Diltiazem; Dipeptides; Enalapril; Guanabenz; Guanidines; Humans; Indapamide; Labetalol; Nifedipine; Pindolol; Verapamil | 1984 |
Hypertensive crisis in children.
Topics: Antihypertensive Agents; Emergencies; Enalapril; Humans; Hypertension; Isradipine; Labetalol; Nicardipine; Nitroprusside | 1996 |
Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety.
Topics: Administration, Intravenous; Antihypertensive Agents; Enalapril; Female; Health Personnel; Hospitals; Humans; Hydralazine; Hypertension; Labetalol; Patient Safety; Quality Improvement; Retrospective Studies | 2019 |